LONDON and NEW YORK, March 29, 2023 OKYO Pharma Limited , an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant. | March 29, 2023
Director acquires shares London and New York, NY, 29 March, 2023 - OKYO Pharma Limited , an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat. | March 29, 2023